Abstract
In this study, 29 patients were hospitalized with a diabetic foot infection and were treated with piperacillin/tazobactam. Of these 23 patients who were evaluated for efficacy of treatment, 22 patients improved or were clinically cured. In seven patients (30%), there was persistence of one of the baseline pathogens. Adverse events were reported in 15 patients (58%), three of which were serious. Piperacillin/tazobactam may be useful as monotherapy in diabetic foot infection giving an adequate clinical response and the level of side effects equivalent to those of other broad-spectrum antibiotics.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Diabetic Foot / complications
-
Diabetic Foot / drug therapy*
-
Drug Combinations
-
Enzyme Inhibitors / adverse effects
-
Enzyme Inhibitors / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Penicillanic Acid / adverse effects
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / therapeutic use
-
Penicillins / adverse effects
-
Penicillins / therapeutic use*
-
Piperacillin / adverse effects
-
Piperacillin / therapeutic use*
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / etiology
-
Tazobactam
Substances
-
Drug Combinations
-
Enzyme Inhibitors
-
Penicillins
-
Penicillanic Acid
-
Tazobactam
-
Piperacillin